New China Rule for Export Certificates of Med Devices Takes Effect May 1

Beijing, April 2026 — A significant regulatory update in China’s medical device export framework takes effect on May 1, 2026: the Regulations on Management of Export Sales Certificates for Medical Devices. The rule introduces a two-tiered certification system (Class I and Class II) and—critically—allows devices manufactured solely for export, even if unregistered in China, to obtain an official export sales certificate provided they comply with Good Manufacturing Practice (GMP) standards. This change addresses a longstanding friction point for international buyers who previously faced documentation gaps despite sourcing from compliant facilities, thereby reshaping cross-border supply chain credibility and responsiveness.

Event Overview

Effective May 1, 2026, the Regulations on Management of Export Sales Certificates for Medical Devices officially enters force. It establishes two distinct categories of export sales certificates: Class I for devices already registered or filed in China, and Class II specifically for devices intended exclusively for export—provided their manufacturers meet China’s GMP requirements. Notably, Class II certification does not require prior domestic registration or filing. The regulation is issued by China’s National Medical Products Administration (NMPA) and applies to all enterprises applying for export sales certificates after the effective date.

Industries Affected

Direct trading enterprises — These firms act as exporters or authorized agents for overseas buyers. Under the previous regime, many struggled to provide NMPA-issued documentation for OEM/ODM products without Chinese market authorization, weakening tender competitiveness and triggering import clearance delays abroad. With Class II certificates now available, such enterprises gain a verifiable, government-issued document that supports customs clearance, regulatory submissions (e.g., FDA 510(k) or EU MDR Annex IV), and buyer due diligence—directly improving contract win rates and reducing pre-shipment verification overhead.

Raw material procurement enterprises — Suppliers of critical components (e.g., biocompatible polymers, sterile packaging films, sensor substrates) often serve multiple tiers of device manufacturers. While not direct applicants for certificates, their traceability systems and supplier qualification records are now subject to heightened scrutiny during GMP audits required for Class II certification. Observably, procurement enterprises may face more frequent requests for audit-ready documentation—including material certifications, stability data, and change control logs—especially when supplying to Class II applicants.

Contract manufacturing enterprises (CMEs) and OEM/ODM manufacturers — This group stands to benefit most operationally. Previously, producing only for export meant forfeiting formal NMPA documentation entirely. Now, CMEs meeting GMP standards can proactively pursue Class II certification, transforming their status from ‘unverified supplier’ to ‘NMPA-recognized exporter’. Analysis shows this shift strengthens negotiation leverage with global brand owners, supports longer-term capacity commitments, and may accelerate integration into multinational quality agreements.

Supply chain service enterprises — Including regulatory consultancies, third-party auditors, and logistics providers offering compliance support: demand for GMP readiness assessments, Class II application package preparation, and post-certification surveillance coordination is expected to rise. From industry perspective, these services are shifting from ‘ad hoc advisory’ toward standardized, repeatable offerings—with pricing models likely evolving toward retainer-based or per-certificate structures rather than one-off project fees.

Key Considerations and Recommended Actions

Verify GMP alignment before application

Applicants must demonstrate full compliance with China’s Good Manufacturing Practice for Medical Devices (Order No. 39), including facility validation, personnel training records, and corrective action tracking. Self-assessment alone is insufficient; NMPA may conduct on-site verification for Class II applications. Enterprises should prioritize gap remediation at least 90 days ahead of submission.

Distinguish Class I vs. Class II eligibility clearly

Devices already registered or filed in China must apply for Class I certificates. Mixing product lines or misclassifying under Class II risks rejection or revocation. Companies with dual-market strategies (China + export) should maintain separate documentation streams and quality system references to avoid cross-contamination of certification status.

Update contractual terms with overseas partners

Buyers increasingly reference Class II certificates in procurement clauses (e.g., ‘certificate valid at time of shipment’). Exporters should review master supply agreements and Incoterms to clarify responsibilities for certificate renewal, validity windows, and liability in case of suspension—particularly given that Class II certificates are valid for up to 2 years and subject to periodic oversight.

Editorial Perspective / Industry Observation

This regulation is better understood not as a standalone policy tweak, but as a strategic calibration in China’s broader industrial diplomacy—aligning domestic regulatory infrastructure with the realities of globalized medtech value chains. Current more noteworthy is how it lowers the barrier for smaller, specialized manufacturers to enter high-compliance export markets without first navigating China’s domestic registration pathway (which remains costly and time-intensive). However, analysis shows adoption will likely be uneven: larger OEMs with existing GMP systems will move swiftly, while SMEs may face capacity constraints in documentation and audit preparation. Also worth monitoring is whether other jurisdictions (e.g., ASEAN, GCC) begin accepting Class II certificates as part of their own import evaluation—potentially expanding its de facto recognition beyond China’s borders.

Conclusion

The introduction of Class II export sales certificates marks a pragmatic step toward harmonizing China’s regulatory posture with global trade expectations. It does not relax safety or quality standards—but rather restructures documentation legitimacy to reflect functional use. For the industry, the lasting significance lies less in immediate paperwork relief and more in the signal it sends: China’s medtech export ecosystem is maturing toward transparency, traceability, and role-specific regulatory tools. Rational observation suggests this will foster deeper integration—not just of Chinese factories, but of Chinese compliance logic—into international supply networks.

Source Attribution

Official text published by the National Medical Products Administration (NMPA) on March 28, 2026 (NMPA Announcement No. 42/2026); supporting guidance released in NMPA’s Q&A on Export Sales Certificate Applications (April 10, 2026). Implementation details—including fee structure, application portal rollout, and criteria for GMP verification frequency—remain pending formal notice and are subject to ongoing observation.